Soki Kashima

Urologist, Surgeon-scientist, Immune-oncology, Kidney cancer, Associate Research Scientist, Faculty @YaleMed @YaleCancer

[Soki Kashima @KashimaMDPhD]

I thrilled to share our review and Beyond the Abstract on “The Changing Landscape of Immunotherapy for Advanced Renal Cancer” from https://t.co/RoiQGjukaU and https://t.co/0DvaVI9VE9
I really appreciate @BraunMDPhD's mentoring
@UroToday @YaleCancer @YaleMed
@UrologicClinics

[UroToday.com @urotoday]

The changing landscape of immunotherapy for advanced #RenalCancer. #BeyondTheAbstract with @KashimaMDPhD and @BraunMDPhD @YaleCancer. #ReadNow on UroToday > https://t.co/uxcobYHIXM @YaleMed @UrologicClinics

[Toni Choueiri, MD @DrChoueiri]

Hard to believe that these 2 super-stars Drs. @RazaneHChehade @MarcMachaalani are moving on after an amazing 3-yr postdoc fellowships in the @DanaFarber_GU labs

Both @PittPediatrics and @YaleIMed are very lucky to have you! Please don’t become @steelers fan or @Yale 🏈 fan!

[tatsunori_shimoi 下井辰徳 @shimoi_oncology]

@waraonc23jp
#ASCO26

藤原先生とお会いできました！
irAEを起こした患者さんのリチャレンジデータのシステマティックレビューとメタアナリシス
再度ICIを投与したら42.2%にirAEは認められる

23.8%に同じirAE再発、でも29.3%は別のirAEが認められたんだって
grade3以上は18.8% grade1-2は27.1%
利益とリスクのSDMのために、とても大切かつ参考になるデータ

[Toni Choueiri, MD @DrChoueiri]

@KCRS26 is shaping up to be another fantastic meeting for the #kidneycancer community. Great science, great conversations, and great people! Hope to see many of you in Boston on July 23–24, or online if you can’t make the trip.

#KCRS26 will bring together leaders in kidney cancer research, clinical care, advocacy, industry, and the patient community.

In-person attendance is limited due to space constraints; however, virtual registration is free and open to all.

Register: https://t.co/KXWoIiUAAx

#KidneyCancer @kidneycan

[ari hakimi @arihakimi]

Why do VEGFR-TKI + IO combinations produce impressive responses in ccRCC but often fail to achieve the long-term durability seen with dual checkpoint blockade? Check out our lab's latest in @Cancer_Cell led by the incredible Lyn Vuong!
https://t.co/ASvkCpDzQW

[Wassim Daoud Khatoun @WDKhatoun]

Honored to have presented our poster today at #ASCO26 about the role of CARINH in predicting progression in mccRCC. Grateful for the exemplary mentorship of @DrChoueiri and @BraunMDPhD!

@ASCO @DanaFarber_GU @DanaFarber @OncoAlert @IMG_Oncologists

[Toni Choueiri, MD @DrChoueiri]

Superstar and incoming intern @MarcMachaalani presenting his poster on prognostic biomarkers in mRCC!

@VincentWenxinXu @ASCO @OncoAlert @IMG_Oncologists @Uromigos
#ASCO26

I’m sure he is going to shine @YaleMed @TradIMYale @YaleIMed @MarkDSiegel1 @BraunMDPhD !

[Yale Cancer Center @YaleCancer]

.@BraunMDPhD and colleagues tested a “live tumor fragment” lab assay/elive platform using biopsies to predict response to ICI. In a small validation (20 pts later treated with ICI) the Elephas score correctly flagged 82% of responders and 100% of non-responders, including 2 responders missed by standard biomarkers. Larger validation is ongoing. #ASCO26 @SmilowCancer @ASCO @OncoAlert

[Yale Cancer Center @YaleCancer]

.@BraunMDPhD & Dr. Zachary Yochum @YaleHemOnc at #ASCO26: Spatial multi-omics mapping of #kidney tumors showed aggressive rhabdoid/sarcomatoid regions are rich in immune cells, with T cells that appear both activated and exhausted. These findings may help explain why some high-risk tumors still respond to checkpoint immunotherapy. @ASCO @SmilowCancer @OncoAlert

[Soki Kashima @KashimaMDPhD]

Thank you for featuring our work. Huge appreciation to all collaborators, patients and their families!
@DrChoueiri @YaleMed @kidneycan @OncoAlert @syudaikouhou @urol_jua

[Yale Cancer Center @YaleCancer]

At #ASCO26, @kashimamdphd @BraunMDPhD share why some #kidneycancer tumors don’t respond to immunotherapy despite having plenty of T cells. Research found many T cells are “exhausted” and unable to fight cancer effectively, likely due to TGF-β signaling. Blocking TGF-β1 helped restore T cell activity, pointing to a potential new way to overcome resistance. @ASCO @SmilowCancer @OncoAlert

[Dana-Farber Lank Center for Genitourinary Oncology @DanaFarber_GU]

We are proud of our GU Clinical Research Director Dr. Brad McGregor @BradMcG04 who just received his @DanaFarber Clinical Innovation Award certificate!

[Masayo Takahashi @masayomasayo]

Good Citizen Paradoxといって世界中で問題になっています。
いろんな意味で治験や規則のハードルが高すぎてその理想論だけででいくと可能性のある治療（適応拡大含む）になかなか患者がアクセスできない。そうしてさまよっている患者を根拠のない粗悪な治療が取り込んで利益をすぐに出している。まじめに開発をしているあるいは待っているGood Citizenが割を食うというパラドックスですね。
そのはざまに何が本当に必要かをわかっている現場の人たちが作る医療も必要になってきています。

[Soki Kashima @KashimaMDPhD]

We wish we could

[高尚威(レーザーキング) @laaerartman]

名古屋から大阪への出張。

​夜、医学部の同級生と飲み、「梅田のどこに泊まっているんだ？ヒルトンか？」と聞かれた。

「いや、アパホテルだ」と答えたときの、彼のきょとんとした顔。

​医者の世界では、学会や出張といえば高級ホテルが当たり前。それが彼らの「常識」だ。
​だが、経営の原理原則から言えば、あり得ない。
もし自社に売り込みに来る営業マンは例え社長だろうとヒルトンに泊まっていたら、私は絶対に取引をしない。

その無駄な経費は、結局誰が払っているのか？ 顧客だ。そんなたるんだコスト感覚を持った企業に、本当に価値あるプロダクトなど作れるわけがない。

​ビジネスの出張は慰安旅行ではない。寝るだけの場所に無駄な金を使う意味がどこにあるのか。機能的で合理的なアパホテルで十分だ。

[ゲノムのほうの愛ちゃん🌙 🐧 @dritoshi]

「AIエージェントを使いこなす はじめてのバイオインフォマティクス開発作法 -- 情報技術の基礎から環境構築・設計・テスト・公開まで」Vibe coding初心者から上級者までフィードバック待ってます!
https://t.co/EvnSxZl4ek

[Soki Kashima @KashimaMDPhD]

@waraonc23jp 6年連続凄いですね！おめでとうございます🎉 私も無事採択されましたので、またシカゴでお会いできるのを楽しみにしております。それまでにTSA lineが落ち着いていると良いのですが、、

[Society for Immunotherapy of Cancer @sitcancer]

Welcome to the 2026 #SITC #Sparkathon participants (Sparkies). We would like to thank them for participating in this unique program to advance their careers in immuno-oncology! #TCells #IO #SITCQuestfor100

[Soki Kashima @KashimaMDPhD]

@MarcMachaalani Congrats, Marc! Welcome to Yale!

[Soki Kashima @KashimaMDPhD]

https://t.co/oZRE5UTGos

[医学書院 販売・PR部 @igs_pr]

【雑誌最新号】
臨床泌尿器科 Vol.80 No.3

特集　腎癌という王都を落とせ──本丸奪還に挑む

https://t.co/EHzxIjKPVX #医学書院 @rinpi

[Hao Yin @HaoYin20]

#SpatialTranscriptomics

Optimizing Xenium @10xGenomics In Situ data utility by quality assessment & best-practice analysis workflows

If you are a Xenium user, this is a must-read🔥

👉Segmentation: Cellpose + Baysor (Segmentation-free alternative: SSAM, Points2Regions)
👉Preprocessing: Library size normalization, log-transformation, scaling, k-nearest neighbors graph (all PCs + 16 neighbors), Louvain clustering
👉Spatially variable feature selection: Squidpy Moran's I, Seurat Moran's I, Sinfonia, SomDE, Giotto, Hotspot
👉Imputation: SpaGE, Seurat, Tangram, SpaOTsc
👉Spatial domain identification: binning-based strategy, Bansky, SPACEL

Performance
vs CosMX, Molecular cartography, MERFISH, MERSCOPE, high-sensitivity ISS

@naturemethods 2025
https://t.co/blSirtI7rG

[Toni Choueiri, MD @DrChoueiri]

Dr. Kato on MONSTAR-SCREEN-3.
Ultra-sensitive ctDNA MRD in resectable RCC:
- Feasible in 100% of patients (16/16)
- Baseline ctDNA detected in 100%; 50% at ultra-low levels
- Post-op MRD+ rates (small numbers): 13.3% (1 mo), 15.4% (3 mo), 10% (6 mo)
- In the only recurrence so far, MRD led imaging by around 4.4 months

Clinical outcomes are awaited to provide further insight into the role of ctDNA in RCC.

#GU26
#RCC
@OncoAlert
@OncBrothers

[Emre Yekedüz @yekeduz_emre]

🎯@DrChoueiri is rocking the stage again on adjuvant tx of #kidneycancer!

Phase 3 LITESPARK-022: In high-risk ccRCC post-nephrectomy, adjuvant pembrolizumab + belzutifan significantly improved DFS vs pembro alone (HR 0.72; 24-mo DFS 80.7% vs 73.7%).

OS immature. Manageable safety; ↑ grade ≥3 AEs (52.1% vs 30.2%).

Potential new SOC!

@ASCO #GU26 @DrChoueiri @DrYukselUrun @OncoAlert @DanaFarber_GU